- Home
- GSHR vs DSGN Comparison
GSHR vs DSGN Comparison
Compare GSHR & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSHR
- DSGN
- Stock Information
- Founded
- GSHR 2024
- DSGN 2017
- Country
- GSHR United States
- DSGN United States
- Employees
- GSHR N/A
- DSGN N/A
- Industry
- GSHR
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- GSHR
- DSGN Health Care
- Exchange
- GSHR NYSE
- DSGN Nasdaq
- Market Cap
- GSHR 205.8M
- DSGN 208.9M
- IPO Year
- GSHR 2025
- DSGN 2021
- Fundamental
- Price
- GSHR $10.12
- DSGN $3.56
- Analyst Decision
- GSHR
- DSGN Hold
- Analyst Count
- GSHR 0
- DSGN 1
- Target Price
- GSHR N/A
- DSGN $4.00
- AVG Volume (30 Days)
- GSHR 2.2K
- DSGN 89.5K
- Earning Date
- GSHR 01-01-0001
- DSGN 08-04-2025
- Dividend Yield
- GSHR N/A
- DSGN N/A
- EPS Growth
- GSHR N/A
- DSGN N/A
- EPS
- GSHR N/A
- DSGN N/A
- Revenue
- GSHR N/A
- DSGN N/A
- Revenue This Year
- GSHR N/A
- DSGN N/A
- Revenue Next Year
- GSHR N/A
- DSGN N/A
- P/E Ratio
- GSHR N/A
- DSGN N/A
- Revenue Growth
- GSHR N/A
- DSGN N/A
- 52 Week Low
- GSHR $9.97
- DSGN $2.60
- 52 Week High
- GSHR $10.25
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- GSHR N/A
- DSGN 36.07
- Support Level
- GSHR N/A
- DSGN $3.65
- Resistance Level
- GSHR N/A
- DSGN $4.21
- Average True Range (ATR)
- GSHR 0.00
- DSGN 0.22
- MACD
- GSHR 0.00
- DSGN -0.06
- Stochastic Oscillator
- GSHR 0.00
- DSGN 0.00
About GSHR GESHER ACQUISITION CORPORATION II ORD USD0.0001 CL A
Gesher Acquisition Corp II is a blank check company.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.